In this study, the effects of polymorphisms of the b 2 and b 3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with b-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing b 2 AR Glu27 or the b 3 AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the b 2 AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after b-blockade was four-fold higher in patients homozygous for the b 2 AR Glu27 variant as compared to b 2 AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic b-blockade treatment.
INTRODUCTION
The antihypertensive treatment with b adrenergic receptor (AR) blockers has been associated with a higher incidence of diabetes, hypercholesterolemia and hypertriglyceridemia. 1 Although the mechanism underlying these adverse events might be intuitive given the presence of b ARs on the liver and their role in the regulation of glucose and lipid homeostasis, the reason why some subjects are more likely to develop adverse events is not completely clear. It is possible to speculate that a genetic background might affect the individual tolerability to the treatment.
The b 2 AR gene displays high genetic variability and common polymorphisms at codons such as Arg16Gly or Glu27Gln and Thr164Ile which could result in altered receptor function. 2 The Glu27 variant has been reported to induce resistance to agonist-promoted downregulation 3 and to increase agonistmediated responsiveness, 4 while the Arg16 allele is associated with enhanced agonist-mediated desensitization. 4 The b 3 AR recognizes most of the b 1 and b 2 AR antagonists as agonists 5 and reveals a lower affinity for catecholamines. 6 Thus, the primary function of this receptor may be to maintain signaling during periods of sustained sympathetic
The Pharmacogenomics Journal (2005) 5, 292-297stimulation 7 and it is considered a prime candidate for the regulation of lypolysis and insulin sensitivity in humans. The polymorphism in the b 3 AR gene, that results in the replacement of Trp by Arg at position 64, is closely associated with abdominal obesity and insulin resistance. 8, 9 b 2 and b 3 AR but not b 1 polymorphisms have been demonstrated to exert an impact on metabolism. In particular, the Glu27Gln genotype of the b 2 AR is associated with elevated triglyceride plasma levels in a Swedish population, 10 while this genotype and the b 3 AR Arg64 allele show a protective effect against metabolic disorders in obese families from southern Poland. 11 On the contrary, recent evidence in a north European cohort of obese patients negates the association between common polymorphisms of the b 1 AR and obesity or lypolisis in isolated fat cells. 12 Altogether the above-mentioned observations allow the speculation that the polymorphisms of the b ARs may contribute to modify the metabolic response to long-term antihypertensive treatment with b-blockers. The present study was undertaken to test the hypothesis that in hypertensive patients a given polymorphism of b 2 and/or b 3 ARs might predict the occurrence of metabolic adverse events during b AR blocking treatment. In particular, we evaluated the effects of known polymorphisms of the b 2 and b 3 AR genes, which are involved in glucose and lipid metabolism, on the occurrence of diabetes and dyslipidemia observed after long-term treatment with b-blockers in hypertensive patients in order to identify possible predictors of individual risk to develop metabolic disorders as side effects of antihypertensive therapy.
METHODS

Patients
A cohort of 1050 white Caucasian patients was recruited from those followed at the outpatient Hypertension Clinic of the Department of Clinical Medicine and Cardiovascular and Immunological Sciences of the Federico II University of Naples and included all the patients who were on treatment with the same drug from at least 6 months and returned to the Outpatient Clinic for a scheduled follow-up control from February 1 to 31 March 2003. At the end of the clinical control the protocol and the aims of the study were illustrated to the patients and those who accepted to participate gave written informed consent and were asked to return in the overnight fasting state for blood sampling for estimation of blood concentration of glucose, total cholesterol and triglycerides and for genotype determination. During the visit, the patients were examined and office blood pressure was measured three times at 2-min interval, with a mercury sphygmomanometer after the patient had been seated for 10 min in a quiet room, according to ISH guidelines. 13 A minimum of three readings was performed, and the average of the last two readings was recorded. Body mass index (BMI) was calculated with the usual formula: weight (kg)/height 2 (m 2 ). Blood glucose, total cholesterol and triglycerides were measured by enzymatic methods using commercial kits.
Determination of Genotypes
The study population was genotyped for the following b adrenergic receptor gene polymorphisms. b 2 Arg16Gly, Glu27Gln and Thr164Ile; b 3 Trp64Arg. We consider wild type the sequences originally described for each gene. Accordingly, the Arg16 of the b 2 AR it is defined as the wild type, although it is the less frequent allele; for the other loci, Gln27 and Thr164 of the b 2 AR and Trp64 of the b 3 AR gene are considered wild-type.
Genomic deoxyribonucleic acid (DNA) was extracted from peripheral lymphocytes with phenol-chloroform followed by ethanol precipitation.
14 Genotyping analysis was conducted by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The PCR was performed as described previously with minor modification. 14 The final 25 ml of PCR mixture contained 14.25 ml of PCR grade water, 2.5 ml of 10 Â PCR buffer (Mg 2 þ ), 1 ml of deoxiribonuclease triphosphatase (2.5 mmol/l each), 2 ml of primer (10 mmol/l each), 0.25 ml of Taq DNA polymerase (5U/ ml; Quiagen) and 5 ml of genomic DNA sample.
For the direct identification of the b 2 polymorphisms, we used the following sense and antisense primers (5 0 -3 0 ): codon 16 (nucleotide 46) ATGGGGCAACCCGGGAACGG and ACGATGAGAGACATGACGATG; codon 27 (nucleotide 79) CCGGGAACGGCAGCGC and ATGGCCAGGACGATGA-GAGAC; codon 164 (nucleotide 491) TTACTTCACCTTT-CAAGTACCAGAGC and CATAGCAGTTGATGGCTTCCTG. Temperature cycling proceeded as follows: initial denaturation for 4 min at 941C, followed by 35 cycles of 30 s at 941C, 30 s at 551C for Thr164Ile, 631C for Glu27Gln and 561C for Arg16Gly, 1 min at 721C, and a terminal extension for 10 min at 721C. The amplified DNA fragments including Arg16Gly polymorphic site were separately digested with NcoI (England Bio labs, Beverly, MA, USA) at 371C for 2 h; those including Glu27Gln polymorphic site were digested with BbvI (England Bio labs, Beverly, MA, USA) at 371C for 2 h and Thr164Ile polymorphic site with MnlI (England Bio Labs, Beverly, MA, USA) at 651C for 1 h. The different patterns of the digested fragments were visualized on ethidium bromide-stained 3% agarose gel. The Trp64Arg b 3 -AR gene polymorphism was identified by PCR performed with 20 ng of genomic DNA with upstream primer 5 0 -CCAGTGGCGTGGCGAGGG-3 0 and downstream primer 5 0 -gccagtggcgcccaacgg-3 0 . The resulting 248 bp product was digested with MvaI (Amersham Pharmacia Biotech). RFLPs were interpreted by three independent investigators (VT, FL, EC), and in case of disagreement, the procedure was performed again. Molecular diagnosis of those cases in which no agreement was obtained was discerned by PCR product sequencing (3100 Avant genetic Analyzer).
Protocol
The study population was divided according to the antihypertensive treatment performed: Group 1) b-blockers (that is atenolol (50-100 mg/die) or metoprolol (100-200 mg/die)), alone or in combination with other antihypertensive drugs; Group 2) other antihypertensive drugs.
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The incidence of diabetes mellitus (antidiabetic therapy and/or fasting blood glucose concentration above 126 mg/dl at least three times 15 by colorimetric assay), hypercholesterolemia (cholesterol-lowering therapy and/or fasting blood cholesterol concentration 4200 mg/dl at least three times 16 by colorimetric assay) , hypertriglyceridemia (documented history of hypertriglyceridemia plus lipid-lowering treatment and/or fasting blood triglyceride concentration 4150 mg/dl at least three times 16 by colorimetric assay) and low HDL (o40 mg/dl at least three times 16 by enzymatic assay) were assessed in the two groups. Then, patients were subdivided according to the presence of each considered polymorphism in the genotype.
Statistical Analysis
Agreement between genotypes observed and those predicted by the Hardy-Weinberg equilibrium was assessed by a w 2 test with one degree of freedom. The results of continuous variables are expressed as means7SE. Before statistical analysis, normal distribution and homogeneity of variables were tested. We used the w 2 test for comparison of proportions and the unpaired t-test for comparison of quantitative variables. Binary logistic regression analysis using the presence of hypertriglyceridemia as dependent variable was performed with a forward step model, in which each variable was inserted in the equation when the tolerance met a 0.0001 level, without changing the tolerance of another variable already in the equation. In this analysis we included BMI, smoke, age, sex, and b 2 AR Glu polymorphism. Multinomial logistic regression was used to asses the impact of the interaction of the b 2 AR genotype (factor) and b-blockade (covariate) on the presence of hypertriglyceridemia (no/yes) using a forward stepwise model in order to exclude from the model those terms that are not significant. From these analyses, we derived information regarding the relative significance of the parameter (Wald) and the relative risk (RR) added with a confidence interval (CI) of 95%. RR was calculated using the wild-type homozygosity condition as referent. The level of statistical significance was set at Po0.05. The statistical analysis was performed with the SPPS 11.0 software (SPSS Inc).
Results
Among the 1050 patients recruited, 80 refused to participate in the study. Thus, we enrolled 970 hypertensive patients whose clinical characteristics are shown in Table 1 . Patients were divided into two groups according to their antihypertensive treatment. There were statistically significant differences between the study groups in sex distribution and, as expected, in heart rate ( Table 1) . On the contrary, no statistically significant difference was detected in the duration of the antihypertensive treatment nor in the percentage of patients that received combination therapy including diuretics ( Table 1 ). The frequencies of the variants of each considered gene are given in Table 2 being not different from those observed in a population of normotensive blood donors (data not shown).
Impact of b AR Gene Polymorphisms on Metabolic Profile
In the overall population, dyslipidemia, that is the evidence of elevated triglycerides and/or cholesterol, occurred in 37.3%, and diabetes was observed in 4.0% of patients. The b 2 AR Glu27 variant was associated with a larger incidence of dyslipidemia (48.4 vs 37.3%, Po0.05) due to an increased proportion of patients with this polymorphism showing elevated serum triglycerides (Gln/Gln: 12.9%; Gln/Glu: 18.6%; Glu/Glu: 25.0%; w 2 : 8.147; Po0.02). The regression analysis showed that the condition of hypertryglyceridemia The impact of the b 3 AR variant Arg64 on the metabolic profile of hypertensive patients also appears to be relevant, since the incidence of dyslipidemia among the bearers of this polymorphism was 55.1 vs 37.3% among the overall population (Po0.05), again due to the increased occurrence of elevated serum triglycerides (Table 3) . No effects were detected of this polymorphism on the occurrence of low HDL (Trp/Arg: 25.0%). Regardless of the drug regimen, the incidence of diabetes among the hypertensives bearing the Arg64 doubled that recorded among the wild-type population, although the statistical significance was not achieved (9.8 vs 4.0%, w 2 ¼ 0.15).
Occurrence of Adverse Metabolic Outcome to b-Blockade
According to bAR Genotype To evaluate the impact of treatment with b-blockers (atenolol or metoprolol) our population of hypertensive The observed allele frequencies are depicted in bold. the expected frequencies according to the Hardy-Weinberg equilibrium, based on the frequency of the less frequent allele are indicated in italics. All frequencies are indicated as percentage. The distribution of the alleles was not different than that predicted from the Hardy-Weinberg equilibrium.
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patients was divided into two groups according to the presence of current assumption of this class of drugs. In the overall population, treatment with b-blockers was not associated with a higher incidence of dyslipidemia (37.4 vs 39.5, NS). No difference in the occurrence of diabetes (3.9 vs 4.7%, NS) was also observed. We then analyzed the impact of the b 2 AR Glu27 and the b 3 AR Arg64 variants on the safety of b-blocker treatment. In agreement with the data obtained in the whole population, among patients not treated with bblockers, those harbouring the Glu27 allele presented a larger occurrence of dyslipidemia when compared with the Gln/Gln group due to an increase in the incidence of elevated serum triglycerides and combined dyslipidemia ( Figure 1 ). Treatment with b-blockers in these patients associates with a further significant increase of elevated serum triglycerids and combined dyslipidemia (Figure 2 ). Multinomial regression analysis showed that the interaction of b-blockade and genotype occurs within the b 2 AR27 Glu/ Glu condition. Indeed, in this group of patients, the bblockade results in a highly statistical significant 4.0-fold increase in the risk to develop hypertriglyceridemia (95% CI: 1.597-10.460). Accordingly, within theGlu/Glu population, b-blockers treatment associates with a larger occurrence of total dyslipidemia (Figure 3) . On the contrary, b blockade in patients harbouring this polymorphism did not change the occurrence of diabetes (Table 4 ) or low HDL (not shown).
The impact of b-blockade in the incidence of dyslipidemia among patients carrying the b 3 AR ARG64 variant resulted in a larger incidence of patients with isolated hypertriglyceridemia, which was about three-fold larger than that recorded among patients with the same allele treated with other antihypertensive drugs, although, again, statistical significance was not achieved on account of the low incidence of this polymorphism in the population (Table  3) . There was no difference in the incidence of diabetes after b blockade in the b 3 ARG64 patients compared to those treated with other antihypertensives (Table 4) .
Discussion
The major finding of our study is the observation that in patients carrying the b 2 AR Glu 27 variant in homozygosity the treatment with b-blockers induced an increase of incidence of dyslipidemia. In fact, in Gln/Gln and Gln/Glu groups b-blocker treatment failed to induce any change of lipid profile. This result is particularly noteworthy, because it allows to identify a subpopulation where the occurrence of dyslipidemia after b blockade is very likely, with an incidence that is above 60%. The identification of this subpopulation makes safer the long-term treatment with bblockers in patients who do not carry the polymorphism and who represent the majority of hypertensive patients.
In the overall population, we found that the b 2 AR Glu 27 variant is associated with a larger occurrence of dyslipidemia due to increased serum triglycerides, independently from treatment. These data are in line with those of Iwamoto et al. 17 and of Ehrenborg et al. 10 who described the same association between the b 2 AR Glu 27 variant and hypertriglyceridemia in unselected populations. The mechanism by which the b 2 AR Glu27 variant is associated with a larger incidence of dyslipidemia is presently unknown. However, the key role of b 2 AR in the regulation of lypolysis is acquired. Indeed, it has been demonstrated that in skeletal muscle, b 2 AR subtype is the only receptor involved in this function, 18 whereas in adipose tissue b 1 and b 3 AR are also involved. 19 The Glu27 is a gain-of-function variant that causes an increase in the b 2 AR signaling, and therefore it is possible to speculate that the resulting physiology is an increased lypolysis, leading to hypertriglyceridemia. Regarding the reasons why b-blocker treatment is associated with an increased incidence of dyslipidemia in patients with the b 2 AR Glu 27 variant, it can be hypothesized that the b 1 AR blockade induced by atenolol or metoprolol, two rather selective b 1 antagonists, 20 may result in the preferential activation of b 2 ARs. The consequence of this phenomenon would be even larger in patients with the b 2 AR genetic variant resulting in dyslipidemia.
The b 3 AR ARG64 variant associated with an increase in dyslipidemia, which was not affected in a significant manner by the treatment with b 1 -blockers. This result is corroborated by a previous observation conducted in an Indian population of young patients affected by coronary artery disease, where the b 3 AR Trp64 polymorphism associates with higher serum triglycerides. 21 These observations suggest the possibility that b 2 and b 3 AR interfere with metabolism through different mechanisms. Such a hypothesis can find support in the different tissue localizations of the two bAR subtypes, with a larger component of b 3 AR at the fat cells, while b 2 AR are more localized in skeletal muscle.
Limitation of the Study
A caveat that the reader has to bear in mind is that this is not a randomized, but rather a post hoc observational study. A series of flaws could derive from this design, like the assignment of patients to treatment upon the discretion of their physician. This is demonstrated by the difference in sex and age between patients on b blockade and patients on other regimens. On the other hand, our results are closer to the daily practice where the physician chooses what he believes is the right treatment based on the anamnestic, physical and instrumental examination. Also, a randomized study would have required a larger effort to follow the same number of patients for such a large number of years needed to detect this side effect. Other drugs are able to interfere with the lipid profile in hypertensives (ie thiazides), although the mechanisms underlying are not completely known. To rule out the confounding effect of other treatments, we repeated the analyses of the incidence of dyslipidemia according to the use of b-blockers as monotherapy, and found results similar to those observed in the bblockers population as a whole (data not shown).
In conclusion, the results of the present study clearly demonstrate that hypertensive patients bearing the Glu27 variant of b 2 AR gene and treated with b-blockers show a higher incidence of dyslipidemia. The relevance of this finding includes the possibility to predict those patients that are highly likely to develop this side effect and consequently to extend to the majority of the patients the benefits of chronic b-blockade.
